750 related articles for article (PubMed ID: 23937855)
1. High-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in locally advanced non-small-cell lung cancer: a feasibility study.
Liu YE; Lin Q; Meng FJ; Chen XJ; Ren XC; Cao B; Wang N; Zong J; Peng Y; Ku YJ; Chen Y
Radiat Oncol; 2013 Aug; 8(1):198. PubMed ID: 23937855
[TBL] [Abstract][Full Text] [Related]
2. Dose escalation of accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in unresectable stage III non-small-cell lung cancer: a phase I trial.
Lin Q; Liu YE; Ren XC; Wang N; Chen XJ; Wang DY; Zong J; Peng Y; Guo ZJ; Hu J
Radiat Oncol; 2013 Aug; 8(1):201. PubMed ID: 23957889
[TBL] [Abstract][Full Text] [Related]
3. Accelerated hypofractionated three-dimensional conformal radiation therapy (3 Gy/fraction) combined with concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer: preliminary results of an early terminated phase II trial.
Ren XC; Wang QY; Zhang R; Chen XJ; Wang N; Liu YE; Zong J; Guo ZJ; Wang DY; Lin Q
BMC Cancer; 2016 Apr; 16():288. PubMed ID: 27108080
[TBL] [Abstract][Full Text] [Related]
4. A modified Phase I trial of radiation dose escalation in 3D conformal radiation therapy with concurrent vinorelbine and carboplatin chemotherapy for non-small-cell lung cancer.
Lin Q; Liu Y; Wang N; Huang Y; Ge X; Ren X; Chen X; Hu J; Guo Z; Zhao Y; Asaumi J
J Radiat Res; 2013 Jan; 54(1):126-34. PubMed ID: 22988282
[TBL] [Abstract][Full Text] [Related]
5. Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium.
Marks LB; Garst J; Socinski MA; Sibley G; Blackstock AW; Herndon JE; Zhou S; Shafman T; Tisch A; Clough R; Yu X; Turrisi A; Anscher M; Crawford J; Rosenman J;
J Clin Oncol; 2004 Nov; 22(21):4329-40. PubMed ID: 15514374
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for Stage III locally advanced, unresectable, non-small-cell lung cancer.
Lee SW; Choi EK; Lee JS; Lee SD; Suh C; Kim SW; Kim WS; Ahn SD; Yi BY; Kim JH; Noh YJ; Kim SS; Koh Y; Kim DS; Kim WD
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):996-1004. PubMed ID: 12829135
[TBL] [Abstract][Full Text] [Related]
7. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
[TBL] [Abstract][Full Text] [Related]
8. Results of a preliminary study using hypofractionated involved-field radiation therapy and concurrent carboplatin/paclitaxel in the treatment of locally advanced non-small-cell lung cancer.
Matsuura K; Kimura T; Kashiwado K; Fujita K; Akagi Y; Yuki S; Murakami Y; Wadasaki K; Monzen Y; Ito A; Kagemoto M; Mori M; Ito K; Nagata Y
Int J Clin Oncol; 2009 Oct; 14(5):408-15. PubMed ID: 19856048
[TBL] [Abstract][Full Text] [Related]
9. Pilot study of accelerated radiotherapy with concurrent chemotherapy for stage III non-small cell lung cancer.
Machtay M; Washam C; Devine P
Semin Oncol; 2005 Apr; 32(2 Suppl 3):S9-12. PubMed ID: 16015530
[TBL] [Abstract][Full Text] [Related]
10. Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy.
Singh AK; Lockett MA; Bradley JD
Int J Radiat Oncol Biol Phys; 2003 Feb; 55(2):337-41. PubMed ID: 12527046
[TBL] [Abstract][Full Text] [Related]
11. A prospective phase II study of induction carboplatin and vinorelbine followed by concomitant topotecan and accelerated radiotherapy (ART) in locally advanced non-small cell lung cancer (NSCLC).
Patel SH; Ajlouni M; Chapman R; Lu M; Movsas B; Kim JH
J Thorac Oncol; 2007 Sep; 2(9):831-7. PubMed ID: 17805061
[TBL] [Abstract][Full Text] [Related]
12. A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancer.
Argiris A; Liptay M; LaCombe M; Marymont M; Kies MS; Sundaresan S; Masters G
Lung Cancer; 2004 Aug; 45(2):243-53. PubMed ID: 15246197
[TBL] [Abstract][Full Text] [Related]
13. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
14. A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117.
Bradley JD; Moughan J; Graham MV; Byhardt R; Govindan R; Fowler J; Purdy JA; Michalski JM; Gore E; Choy H
Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):367-72. PubMed ID: 20457350
[TBL] [Abstract][Full Text] [Related]
15. Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: preclinical and early clinical data.
Reboul FL
Hematol Oncol Clin North Am; 2004 Feb; 18(1):41-53. PubMed ID: 15005280
[TBL] [Abstract][Full Text] [Related]
16. Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: a preliminary report of a phase I dose escalation trial from the Carolina Conformal Therapy Consortium.
Socinski MA; Marks LB; Garst J; Sibley GS; Blackstock W; Turrisi A; Herndon J; Zhou S; Anscher M; Crawford J; Shafman T; Rosenman J
Oncologist; 2001; 6 Suppl 1():20-4. PubMed ID: 11182001
[TBL] [Abstract][Full Text] [Related]
17. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001.
Langer CJ; Movsas B; Hudes R; Schol J; Keenan E; Kilpatrick D; Yeung C; Curran W
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-89-S12-95. PubMed ID: 9331129
[TBL] [Abstract][Full Text] [Related]
18. Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer.
Stinchcombe TE; Morris DE; Lee CB; Moore DT; Hayes DN; Halle JS; Rivera MP; Rosenman JG; Socinski MA
J Thorac Oncol; 2008 Mar; 3(3):250-7. PubMed ID: 18317067
[TBL] [Abstract][Full Text] [Related]
19. High-dose concurrent chemo-proton therapy for Stage III NSCLC: preliminary results of a Phase II study.
Oshiro Y; Okumura T; Kurishima K; Homma S; Mizumoto M; Ishikawa H; Onizuka M; Sakai M; Goto Y; Hizawa N; Sato Y; Sakurai H
J Radiat Res; 2014 Sep; 55(5):959-65. PubMed ID: 24864278
[TBL] [Abstract][Full Text] [Related]
20. Predictors of acute esophagitis in patients with non-small-cell lung carcinoma treated with concurrent chemotherapy and hyperfractionated radiotherapy followed by surgery.
Patel AB; Edelman MJ; Kwok Y; Krasna MJ; Suntharalingam M
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1106-12. PubMed ID: 15519781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
